Key Highlights

  • Third quarter loss per share was USD 0.07, narrower than the estimated loss of USD 0.12, with no Revenue reported.
  • Cash was USD 11.7 million, and the filing says projected outflows raise substantial doubt about continuing as a going concern.
  • The FDA authorized a Phase 2 rexaceract study in Parkinson's disease, anticipated to begin in the first quarter of 2027.
  • Nine-month net loss was USD 13.4 million, and Research and Development spending fell USD 1.5 million to USD 6.3 million.

Gain Therapeutics (NASDAQ:GANX), a clinical-stage company developing an oral small molecule for Parkinson's disease, reported a third quarter 2026 loss of USD 0.07 per share. That was narrower than the USD 0.12 estimated loss. The company reported no revenue. Net loss for the quarter was USD 3.2 million, and for the nine months it was USD 13.4 million.

Research and development expenses for the nine months decreased USD 1.5 million to USD 6.3 million, while general and administrative expenses rose USD 0.5 million to USD 6.9 million. The accumulated Deficit stood at USD 114.8 million, compared with USD 101.4 million at the end of 2025.

Liquidity and Going Concern Language

Cash and cash equivalents were USD 11.7 million at September 30, down from USD 20.8 million at year end. The filing states that projected cash outflows raise substantial doubt about the company's ability to continue as a going concern for at least 12 months from the issuance of the financial statements. It also states that the company states current cash is sufficient to fund operating and Capital requirements into the second quarter of 2027.

During the third quarter the company sold 978,260 shares under its 2024 at-the-market program at an average price of USD 1.88, for gross proceeds of USD 1.8 million. For the nine months it sold 1,941,962 shares at an average of USD 1.96, for gross proceeds of USD 3.8 million. Since the program began, it has sold 10,389,769 shares for gross proceeds of USD 25.7 million.

Rexaceract Development Path

The FDA authorized the company's Investigational New Drug application for rexaceract in June 2026, allowing a Phase 2a study in people with Parkinson's disease, with or without a GBA1 mutation. The study is planned to run at sites in the United States, Australia and Europe, with initiation anticipated in the first quarter of 2027. The company states it plans to submit the protocol for approval in the fourth quarter of 2026.

In the Phase 1b study, 19 patients completed Part 1 and 16 chose to continue daily oral dosing. Part 2 is scheduled for completion in the fourth quarter of 2026. In October 2026 the company presented data for 13 evaluable patients at an international Parkinson's congress in Seoul, showing stabilization of motor symptom scores over 360 days of dosing, which it said supports its disease-modifying hypothesis.

Legal Disclosures and Items to Follow

The quarterly filing describes a lawsuit filed on January 21, 2026 in the United States District Court for the District of Delaware by an individual Warrant holder against the company and its chief executive. The complaint alleged that an agreement to amend the exercise price of the plaintiff's warrants was not honored. After the defendants moved to dismiss, an amended complaint filed April 14, 2026 asserts claims including breach of contract and fraudulent inducement. These are allegations in a court filing, and the matter is described as pending in the company's filing.

The main markers are how the company funds operations beyond the second quarter of 2027, completion of Part 2 of the Phase 1b study, the protocol submission and the start of Phase 2a dosing. Developments in the pending Delaware case are also disclosed in the company's filings.